Correlation Between Halozyme Therapeutics and Henry Schein

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Halozyme Therapeutics and Henry Schein at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Halozyme Therapeutics and Henry Schein into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Halozyme Therapeutics and Henry Schein, you can compare the effects of market volatilities on Halozyme Therapeutics and Henry Schein and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Halozyme Therapeutics with a short position of Henry Schein. Check out your portfolio center. Please also check ongoing floating volatility patterns of Halozyme Therapeutics and Henry Schein.

Diversification Opportunities for Halozyme Therapeutics and Henry Schein

0.23
  Correlation Coefficient

Modest diversification

The 3 months correlation between Halozyme and Henry is 0.23. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and Henry Schein in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Henry Schein and Halozyme Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Halozyme Therapeutics are associated (or correlated) with Henry Schein. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Henry Schein has no effect on the direction of Halozyme Therapeutics i.e., Halozyme Therapeutics and Henry Schein go up and down completely randomly.

Pair Corralation between Halozyme Therapeutics and Henry Schein

Given the investment horizon of 90 days Halozyme Therapeutics is expected to under-perform the Henry Schein. But the stock apears to be less risky and, when comparing its historical volatility, Halozyme Therapeutics is 1.1 times less risky than Henry Schein. The stock trades about -0.19 of its potential returns per unit of risk. The Henry Schein is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  6,955  in Henry Schein on September 11, 2025 and sell it today you would earn a total of  489.00  from holding Henry Schein or generate 7.03% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Halozyme Therapeutics  vs.  Henry Schein

 Performance 
       Timeline  
Halozyme Therapeutics 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Halozyme Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in January 2026. The recent disarray may also be a sign of long period up-swing for the firm investors.
Henry Schein 

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Henry Schein are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady forward indicators, Henry Schein may actually be approaching a critical reversion point that can send shares even higher in January 2026.

Halozyme Therapeutics and Henry Schein Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Halozyme Therapeutics and Henry Schein

The main advantage of trading using opposite Halozyme Therapeutics and Henry Schein positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Halozyme Therapeutics position performs unexpectedly, Henry Schein can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Henry Schein will offset losses from the drop in Henry Schein's long position.
The idea behind Halozyme Therapeutics and Henry Schein pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Complementary Tools

Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities